Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $20.60

Posted by Francis Steltz on Aug 24th, 2026

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.60.

A number of research firms have weighed in on BCRX. Cantor Fitzgerald upped their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Citizens Jmp boosted their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target for the company.

View Our Latest Research Report on BioCryst Pharmaceuticals

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $238,930,000. Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after acquiring an additional 482,494 shares in the last quarter. RA Capital Management L.P. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $123,452,000. Deerfield Management Company L.P. boosted its holdings in BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the last quarter. Finally, State Street Corp grew its stake in BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after purchasing an additional 1,265,773 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 0.1%

Shares of BioCryst Pharmaceuticals stock opened at $9.56 on Friday. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -6.37 and a beta of 0.56. The company has a fifty day moving average price of $9.63 and a 200 day moving average price of $8.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same period last year, the company posted $0.15 earnings per share. The firm’s revenue was up 33.6% compared to the same quarter last year. Analysts forecast that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.